July 19, 2017 - By Marry Poplack

Investors sentiment decreased to 0.03 in 2016 Q4. Its down 0.97, from 1 in 2016Q3. It dived, as 32 investors sold Provectus Biopharmaceuticals Inc shares while 0 reduced holdings. 1 funds opened positions while 0 raised stakes. 110,255 shares or 98.92% less from 10.19 million shares in 2016Q3 were reported.
Fincl Counselors holds 12,600 shares. New York-based Focused Wealth has invested 0% in Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT). Cutter Company Brokerage has 79,500 shares for 0% of their portfolio. Huntington Bancorp reported 200 shares. 10,000 are owned by Hudson Canyon Counselors Ltd Liability. Glenmede Trust Na accumulated 5,000 shares.

The stock of PROVECTUS BIOPHARMACEUTICALS INCORPORATE (OTCMKTS:PVCT) registered an increase of 87.04% in short interest. PVCT’s total short interest was 161,600 shares in July as published by FINRA. Its up 87.04% from 86,400 shares, reported previously. With 934,700 shares average volume, it will take short sellers 0 days to cover their PVCT’s short positions.

The stock decreased 1.67% or $0.0005 on July 19, reaching $0.0295. About 286,930 shares traded. Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) has 0.00% since July 19, 2016 and is . It has underperformed by 16.70% the S&P500.

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The company has market cap of $10.57 million. The Firm is engaged in developing pharmaceuticals for oncology and dermatology indications. It currently has negative earnings. The Firm is focused on developing its prescription drug candidates, PV-10 and PH-10.

More notable recent Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) news were published by: which released: “The Provectus PV-10 Dilemma” on January 22, 2015, also with their article: “Provectus: The Dynamics Of High Risk, High Reward” published on December 08, 2014, published: “The Product Development Story Of Provectus Biopharmaceuticals” on July 28, 2014. More interesting news about Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) were released by: and their article: “63% Implosion: The Epic Collapse of Provectus Biopharmaceuticals, Inc” published on May 27, 2014 as well as‘s news article titled: “Provectus Biopharmaceuticals Enters Into Definitive Financing Commitment Term …” with publication date: March 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: